Serum Procalcitonin and Neutrophil Toxic Granules Guided Management of Post-Operative K. pneumoniae Septic-Shock in Laminectomy—A Case Report


Introduction: We still rely on clinical diagnosis for initiating empirical antibiotic therapy and await blood culture for confirmation of infection, species identification and drug sensitivity. Differential blood cell count (WBC and neutrophils) and recording of toxic granules in the neutrophils are established methods for indirect diagnosis of infection though they are not used in the diagnosis of sepsis per se. Serum Procalcitonin is considered as a good biomarker in the management of sepsis. Materials and Methods: Whole blood and serum were used for laboratory analysis. We have combined the detection of toxic granules in the peripheral blood smear and serum PCT levels for diagnosis and monitoring the recovery of a patient with septic shock. A 63 year old laminectomy patient was transferred 2 days after the surgery to our hospital with several co-morbidities and complications. He was in septic shock and was put on Continuous Renal Replacement Therapy, with ionotropic support and IV fluids via nasogastric feeding and administration of Activated Protein C. Blood culture and daily measurements of serum Procalcitonin, differential blood cells count, and observation of toxic granules in neutrophils were done. Results: The blood culture showed infection due to K. pneumoniae resistant to carbapenems. WBC and Neutrophil counts were quite variable and showed incoherent response to treatment. Serum PCT was 24.57 ng/mL on the next day of admission and it peaked at 30.2 ng/mL on day 3. Its level started decreasing from the 4th day. Toxic granules disappeared when serum PCT levels reached < 1 ng/mL. The patient responded well to treatment and he was discharged on the 16th day upon request. Conclusion: This case is presented as an example of managing sepsis with a combination of a conventional hematology marker and a modern biomarker. Resource poor hospitals with inadequate microbiology services, may evaluate and use these two biomarkers not only for the total management of sepsis but also to reduce the cost of critical care.

Share and Cite:

I. Chivukula, P. K. Marx, K. S. Ratnakar, G. Subbaiah and V. Sritharan, "Serum Procalcitonin and Neutrophil Toxic Granules Guided Management of Post-Operative K. pneumoniae Septic-Shock in Laminectomy—A Case Report," Advances in Infectious Diseases, Vol. 2 No. 3, 2012, pp. 72-75. doi: 10.4236/aid.2012.23011.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] J.-L. Vincent and E. Abraham, “The Last 100 Years of Sepsis,” American Journal of Respiratory and Critical Care Medicine, Vol. 173, No. 3, 2006, pp. 256-263. doi:10.1164/rccm.200510-1604OE
[2] S. Chatterjee, S. Todi, S. Sahu and M. Bhattacharyya, “Epidemiology of Severe Sepsis in India,” Critical Care, Vol. 13, Suppl. 1, 2009, p. 345.
[3] L. A. Al-Gwaiz and H. H. Babay. The Diagnostic Value of Absolute Neutrophil Count, Band Count and Morphologic Changes of Neutrophils in Predicting Bacterial Infections,” Medical Principles and Practice, Vol. 16, No. 5, 2007, pp. 344-347. doi:10.1159/000104806
[4] A. Nakamura, H. Wada, M. Ikejiri, T. Hatada, H. Sakurai, Y. Matsushima, J. Nishioka, K. Maruyama, S. Isaji, T. Takeda and T. Nobori, “Efficacy of Procalcitonin in the Early Diagnosis of Bacterial Infections in a Critical Care Unit,” Shock, Vol. 31, No. 6, 2009, pp. 586-591. doi:10.1097/SHK.0b013e31819716fa
[5] L. Simon, F. Gauvin, D. K. Amre, P. Saint-Louis and J. Lacroix. “Serum Procalcitonin and C-Reactive Protein Levels as Markers of Bacterial Infection: A Systematic Review and Meta-Analysis,” Clinical Infectious Diseases, Vol. 39, No. 2, 2004, pp. 206-217. doi:10.1097/SHK.0b013e31819716fa
[6] A. van de Vyver, E. F. Delport, M. Esterhuizen and R. Pool, “The Correlation between C-Reactive Protein and Toxic Granulation of Neutrophils in the Peripheral Blood,” South African Medical Journal, Vol. 100, No. 7, 2010, pp. 442-444.
[7] P. Schuetz, W. Albrich, M. Christ-Crain, J. Chastre and B. Mueller, “Procalcitonin for Guidance of Antibiotic Therapy,” Expert Reviews in Anti Infectives Therapy, Vol. 8, No. 5, 2010, pp. 575-587. doi:10.1586/eri.10.25
[8] P. Emmanuel Charles, E. Kus, S. Aho, S. Prin, J.-M. Doise, N.-O. Olsson, B. Blettery and J.-P. Quenot, “Serum Procalcitonin for the Early Recognition of Nosocomial Infection in the Critically Ill Patients: A Preliminary Report,” BMC Infectious Diseases, Vol. 9, No. 1, 2009, pp. 49-58.
[9] J. U. Jensen, L. Heslet, T. H. Jensen, K. Espersen, P. Steffensen and M. Tvede, “Procalcitonin Increase in Early Identification of Critically Ill Patients at High Risk of Mortality,” Critical Care Medicine, Vol. 34, No. 10, 2006, pp. 2596-2602. doi:10.1097/01.CCM.0000239116.01855.61
[10] C. Pierrakos and J. L. Vincent, “Sepsis Biomarkers: A Review,” Critical Care, Vol. 14, No. 1, 2010, p. R15. doi:10.1186/cc8872
[11] J. C. Singh and N. S. Kekre, “Procalcitonin: A Marker for Renal Parenchymal Infection in Children?” Indian Journal of Urology, Vol. 22, No. 2, 2006, pp. 162-63.
[12] S. K. Todi, “Top Stories of 2009,” Indian Journal of Critical Care Medicine, Vol. 14, No. 1, 2010, pp. 3-7. doi:10.4103/0972-5229.63027
[13] U. Sudhir, R. K. Venkatachaliah, T. Anilkumar, M. Yogeshwar Rao and P. Kempegowda, “Significance of Serum Procalcitonin in Sepsis,” Indian Journal of Critical Care Medicine, Vol. 15, No. 1, 2011, pp. 1-5. doi:10.4103/0972-5229.78214
[14] M. Sinha, S. Desai, S. Mantri and A. Kulkarni, “Procalcitonin as an Adjunct Biomarker in Sepsis,” Indian Journal of Anesthesia, Vol. 55, No. 3, 2011, pp. 266-270. doi:10.4103/0019-5049.82676
[15] M. Meisner, “PCT in the Differential Diagnosis of Viral and Bacterial Infections,” In: M. Meisner, Ed., Procalcitonin—A New Innovative Infection Parameter Biochemical and Clinical Aspects, 3rd Edition, Thieme Verlag, Stuttgart, 2000, pp 136-37.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.